Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

5.69
+0.620012.23%
Post-market: 5.730.0372+0.65%19:46 EDT
Volume:351.92K
Turnover:1.90M
Market Cap:97.75M
PE:-3.27
High:5.86
Open:5.12
Low:5.00
Close:5.07
52wk High:9.82
52wk Low:3.28
Shares:17.18M
Float Shares:6.78M
Volume Ratio:2.31
T/O Rate:5.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7400
EPS(LYR):-1.6791
ROE:-240.35%
ROA:-43.98%
PB:22.70
PE(LYR):-3.39

Loading ...

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

TIPRANKS
·
Aug 27

Lake Street starts Verrica Pharmaceuticals with a Buy

TIPRANKS
·
Aug 27

Verrica Completes Enrollment in Phase 3 COVE-2 Trial of Ycanth for Common Warts, Sees Data in Q1 2027

Reuters
·
Aug 27

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (Cove-2) Evaluating Ycanth® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

THOMSON REUTERS
·
Aug 27

Verrica Pharmaceuticals - Topline Data from Cove-2 Expected in Q1 2027

THOMSON REUTERS
·
Aug 27

Verrica Pharmaceuticals CEO buys $125.8K in common stock

TIPRANKS
·
Aug 19

Verrica Interim CFO John J. Kirby Acquires $24,650 of Common Shares

Reuters
·
Aug 19

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)

TIPRANKS
·
Aug 08

Verrica Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Verrica Pharma Reports Wider-than-Expected Q2 Adj Loss Per Share

Reuters
·
Aug 07

Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate

Benzinga Earnings
·
Aug 07

Verrica Pharmaceuticals Q2 Income from Operations USD -13.097 Million

THOMSON REUTERS
·
Aug 07

Verrica Pharmaceuticals Q2 Adjusted EPS USD -0.48

THOMSON REUTERS
·
Aug 07

Verrica Pharmaceuticals Closes Credit Facility for up to $27.5 Million with Entity Controlled by Chairman Paul Manning

Reuters
·
Aug 07

Verrica Pharmaceuticals Closes Credit Facility for up to $27.5 Million in Non-Dilutive Growth Capital

THOMSON REUTERS
·
Aug 07

Verrica Pharmaceuticals Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Verrica Pharmaceuticals Schedules Conference Call to Discuss Q2 Results, Corporate Update

Reuters
·
Jul 30

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

THOMSON REUTERS
·
Jul 30

Verrica Signs Exclusive Deal with Medomie to Market Ycanth in Israel

Reuters
·
Jul 21

Verrica Pharmaceuticals: Granted Medomie Exclusive Right to Obtain & Maintain Marketing Authorizations for Ycanth in Israel

THOMSON REUTERS
·
Jul 21